Peak Human ShopRetatrutide (The Triple-G Peptide)
RET · 10 / 15 / 20 / 30 mg · Pre-filled pen, cartridge refill, or vial
Research use only
An investigational GLP-1 / GIP / glucagon triple receptor agonist studied in Phase 2 and Phase 3 trials for weight management, metabolic regulation, and liver fat reduction.
Triple agonist
GLP-1 + GIP + glucagon receptors
Weekly protocol
Subcutaneous
Trial-leading results
~28–30% weight loss in Phase 3
Physician-vetted
Curated by Dr. Sanjeev Goel
from $320 CAD
on Peak Human Shop (CAD)Three receptors, one molecule.
GLP-1 receptor activation reduces appetite and improves glucose-dependent insulin secretion.
GIP receptor activation enhances fat metabolism and energy expenditure.
Glucagon receptor activation raises hepatic energy expenditure, thermogenesis and fat oxidation, and reduces liver fat.
The three pathways synergize, producing an impact beyond single- or dual-agonist drugs.
Phase 2 and Phase 3 findings in NEJM and Nature Medicine.
Each figure below is attributable to the specific trial cited and describes the compound studied in that trial.
New England Journal of Medicine, 2023
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al.
At the 12 mg dose, participants lost a mean of 24.2% of body weight at 48 weeks.
Read studyNature Medicine, 2024
Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial
Sanyal AJ, et al.
~82% relative reduction in liver fat; 86% of participants reached normal liver fat (<5%) at 24 weeks.
Read studyEli Lilly — Phase 3 TRIUMPH-1, 2025
TRIUMPH-1: Pivotal Phase 3 obesity trial (n=2,339)
Eli Lilly and Company
28.3% average weight loss at 80 weeks (12 mg), up to 30.3% in a 104-week subgroup; 45.3% of participants lost ≥30% of body weight.
Read studyEli Lilly — Phase 3 TRIUMPH-4, Dec 2025
TRIUMPH-4: Obesity + knee osteoarthritis (n=445)
Eli Lilly and Company
28.7% weight loss (efficacy estimand), a 14 mmHg systolic blood-pressure reduction, and meaningful knee-osteoarthritis pain relief at 68 weeks.
Read studyMore drug, more effect — a clear dose response.
Phase 3 TRIUMPH-1, 80 weeks, efficacy estimand (Eli Lilly, 2025; n=2,339). Mean body-weight reduction reached 28.3% at the 12 mg dose versus 2.2% for placebo; 45.3% of participants on 12 mg lost ≥30% of body weight, and a 104-week maximum-tolerated-dose subgroup reached 30.3%. Each figure is attributable to that specific trial and describes the compound studied in it. View the source study
Research use only — investigational, not FDA-approved.
Retatrutide is for research use only. It is an investigational compound and is not FDA-approved. This page summarizes published clinical research and is not medical advice or a treatment promise. The figures above are attributable to the specific trials cited and describe the compound studied in those trials — not a guaranteed outcome of any product. Peak Human products are intended for adults under the guidance of a qualified healthcare provider. GLP-1/GIP/glucagon agonists carry potential side effects including nausea, gastrointestinal discomfort, and increased heart rate.
Related on Peak Human
Retatrutide — curated by Dr. Goel.
Ships from Peak Human Shop. Investigational compound — use only under qualified medical supervision.